{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pleural+Mesothelioma+Malignant&page=7", "query": { "condition": "Pleural Mesothelioma Malignant", "page": 7 }, "page_size": 10 }, "pagination": { "page": 7, "page_size": 10, "total_count": 198, "total_pages": 20, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pleural+Mesothelioma+Malignant&page=8&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Pleural+Mesothelioma+Malignant&page=6&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T17:38:15.215Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03228537", "title": "Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Biphasic Mesothelioma", "Epithelioid Mesothelioma", "Stage I Pleural Diffuse Malignant Mesothelioma AJCC v7", "Stage IA Pleural Diffuse Malignant Mesothelioma AJCC v7", "Stage IB Pleural Diffuse Malignant Mesothelioma AJCC v7", "Stage II Pleural Diffuse Malignant Mesothelioma AJCC v7", "Stage III Pleural Diffuse Malignant Mesothelioma AJCC v7" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Extrapleural Pneumonectomy", "type": "PROCEDURE" }, { "name": "Pemetrexed Disodium", "type": "DRUG" }, { "name": "Pleurectomy", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2018-07-16", "completion_date": "2027-09-18", "has_results": true, "last_update_posted_date": "2026-10-22", "last_synced_at": "2026-10-30T17:38:15.215Z", "location_count": 174, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 121 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Hot Springs", "state": "Arkansas" }, { "city": "Arroyo Grande", "state": "California" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03228537" }, { "nct_id": "NCT02568449", "title": "Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Pleural Malignant Mesothelioma", "Stage IV Pleural Mesothelioma" ], "interventions": [ { "name": "Nintedanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2016-03-15", "completion_date": "2018-06-26", "has_results": true, "last_update_posted_date": "2021-12-09", "last_synced_at": "2026-10-30T17:38:15.215Z", "location_count": 3, "location_summary": "Ann Arbor, Michigan • Detroit, Michigan • New York, New York", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02568449" }, { "nct_id": "NCT00030498", "title": "Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Anaplastic Astrocytoma", "Adult Anaplastic Ependymoma", "Adult Anaplastic Oligodendroglioma", "Adult Brain Stem Glioma", "Adult Diffuse Astrocytoma", "Adult Ependymoblastoma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Adult Mixed Glioma", "Adult Myxopapillary Ependymoma", "Adult Oligodendroglioma", "Adult Pilocytic Astrocytoma", "Adult Primary Hepatocellular Carcinoma", "Adult Subependymoma", "Advanced Adult Primary Liver Cancer", "Advanced Malignant Mesothelioma", "Male Breast Cancer", "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity", "Recurrent Adult Brain Tumor", "Recurrent Adult Primary Liver Cancer", "Recurrent Anal Cancer", "Recurrent Basal Cell Carcinoma of the Lip", "Recurrent Bladder Cancer", "Recurrent Breast Cancer", "Recurrent Cervical Cancer", "Recurrent Colon Cancer", "Recurrent Esophageal Cancer", "Recurrent Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Lymphoepithelioma of the Nasopharynx", "Recurrent Lymphoepithelioma of the Oropharynx", "Recurrent Malignant Mesothelioma", "Recurrent Metastatic Squamous Neck Cancer With Occult Primary", "Recurrent Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity", "Recurrent Non-small Cell Lung Cancer", "Recurrent Ovarian Epithelial Cancer", "Recurrent Pancreatic Cancer", "Recurrent Prostate Cancer", "Recurrent Rectal Cancer", "Recurrent Salivary Gland Cancer", "Recurrent Squamous Cell Carcinoma of the Hypopharynx", "Recurrent Squamous Cell Carcinoma of the Larynx", "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity", "Recurrent Squamous Cell Carcinoma of the Nasopharynx", "Recurrent Squamous Cell Carcinoma of the Oropharynx", "Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Recurrent Verrucous Carcinoma of the Larynx", "Recurrent Verrucous Carcinoma of the Oral Cavity", "Stage II Esophageal Cancer", "Stage II Pancreatic Cancer", "Stage III Esophageal Cancer", "Stage III Pancreatic Cancer", "Stage IIIB Non-small Cell Lung Cancer", "Stage IV Adenoid Cystic Carcinoma of the Oral Cavity", "Stage IV Anal Cancer", "Stage IV Basal Cell Carcinoma of the Lip", "Stage IV Bladder Cancer", "Stage IV Breast Cancer", "Stage IV Colon Cancer", "Stage IV Esophageal Cancer", "Stage IV Esthesioneuroblastoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Inverted Papilloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Lymphoepithelioma of the Nasopharynx", "Stage IV Lymphoepithelioma of the Oropharynx", "Stage IV Midline Lethal Granuloma of the Paranasal Sinus and Nasal Cavity", "Stage IV Mucoepidermoid Carcinoma of the Oral Cavity", "Stage IV Non-small Cell Lung Cancer", "Stage IV Ovarian Epithelial Cancer", "Stage IV Pancreatic Cancer", "Stage IV Prostate Cancer", "Stage IV Rectal Cancer", "Stage IV Salivary Gland Cancer", "Stage IV Squamous Cell Carcinoma of the Hypopharynx", "Stage IV Squamous Cell Carcinoma of the Larynx", "Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity", "Stage IV Squamous Cell Carcinoma of the Nasopharynx", "Stage IV Squamous Cell Carcinoma of the Oropharynx", "Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity", "Stage IV Verrucous Carcinoma of the Larynx", "Stage IV Verrucous Carcinoma of the Oral Cavity", "Stage IVA Cervical Cancer", "Stage IVB Cervical Cancer", "Unspecified Adult Solid Tumor, Protocol Specific", "Untreated Metastatic Squamous Neck Cancer With Occult Primary" ], "interventions": [ { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2001-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-10-30T17:38:15.215Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00030498" }, { "nct_id": "NCT03436732", "title": "Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mesothelioma" ], "interventions": [ { "name": "LMB-100", "type": "DRUG" }, { "name": "SEL-110", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 5, "start_date": "2018-02-28", "completion_date": "2019-04-30", "has_results": true, "last_update_posted_date": "2019-11-22", "last_synced_at": "2026-10-30T17:38:15.215Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03436732" }, { "nct_id": "NCT05932199", "title": "Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mesothelioma" ], "interventions": [ { "name": "Durvalumab / tremelimumab", "type": "DRUG" }, { "name": "Platinum cisplatin or carboplatin and pemetrexed chemotherapy plus durvalumab/tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Baylor College of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2024-07-03", "completion_date": "2028-05-31", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-30T17:38:15.215Z", "location_count": 2, "location_summary": "Durham, North Carolina • Houston, Texas", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05932199" }, { "nct_id": "NCT01843374", "title": "Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Unresectable Pleural or Peritoneal Malignant Mesothelioma" ], "interventions": [ { "name": "Tremelimumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 571, "start_date": "2013-05-17", "completion_date": "2027-05-31", "has_results": true, "last_update_posted_date": "2026-07-27", "last_synced_at": "2026-10-30T17:38:15.215Z", "location_count": 21, "location_summary": "Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 17 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01843374" }, { "nct_id": "NCT00028782", "title": "EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Advanced Malignant Mesothelioma", "Localized Malignant Mesothelioma", "Malignant Ascites", "Primary Peritoneal Cavity Cancer", "Recurrent Malignant Mesothelioma" ], "interventions": [ { "name": "etanidazole", "type": "DRUG" }, { "name": "therapeutic conventional surgery", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2001-10", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-16", "last_synced_at": "2026-10-30T17:38:15.215Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00028782" }, { "nct_id": "NCT00604461", "title": "Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Mesothelioma" ], "interventions": [ { "name": "Carboplatin, Bevacizumab and Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "H. Lee Moffitt Cancer Center and Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2007-10", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2017-03-23", "last_synced_at": "2026-10-30T17:38:15.215Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00604461" }, { "nct_id": "NCT00020579", "title": "MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "entinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 75, "start_date": "2001-03", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2012-03-15", "last_synced_at": "2026-10-30T17:38:15.215Z", "location_count": 3, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00020579" }, { "nct_id": "NCT06477419", "title": "A Study of Sacituzumab Govitecan in People With Mesothelioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mesothelioma", "Mesotheliomas Pleural", "Mesothelioma; Pleura" ], "interventions": [ { "name": "Sacituzumab govitecan-hziy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2024-06-21", "completion_date": "2029-06-21", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-10-30T17:38:15.215Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06477419" } ] }